RxDoctor Payments Data

Devin Tran, MD

Ophthalmology · Baton Rouge, LANPI 1710391099

Payments from drug & device makers

$5,349in general payments, 2019–2025

Across 147 payments — averaging $36.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • Glaukos Corporation$2K
  • Biotissue Holdings Inc.$582
  • AbbVie$297
  • Oyster Point Pharma, Inc.$228
  • Rxsight Inc$146
  • plus $816 from 14 others

What the payments were for

  • Food & beverage$5,349100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,349 in reported general payments places this provider in the 75th percentile of 286 ophthalmology providers in Louisiana.

See all ophthalmology providers in Louisiana

Medicare billing

Part B allowed, 2024
$180,472
Medicare patients
448
Services billed
1,333

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine60$50,606
Prednisolone Acetate305$16,349
MieboPerfluorohexyloctane/Pf18$13,158
XiidraLifitegrast11$7,868
RocklatanNetarsudil Mesylat/Latanoprost24$7,828
Fluorometholone72$6,626
RhopressaNetarsudil Mesylate19$6,157
LumiganBimatoprost17$5,486
Cyclosporine14$5,325
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol33$4,729
Loteprednol Etabonate22$3,708
ValacyclovirValacyclovir Hcl72$3,452
Latanoprost280$3,019
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat95$1,772
MoxifloxacinMoxifloxacin Hcl87$1,650

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$297$56,09177 claims
Bausch & Lomb Americas Inc.Miebo, Xiidra$76$21,02529 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$54$13,98543 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$25$3,70822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 286 ophthalmology providers in Louisiana.

Other ophthalmology in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →